Table of Contents
NAD+ declines with age. Below is a visualization of the timeline of expected improvements with Dripdok, due to our proprietary delivery designed to enhance mitochondrial uptake and reduce AMP metabolites.
Expected Progress Timeline #
| Timeframe | Expected Improvements | Key Monitoring Markers |
|---|---|---|
| Days 1–7 | Initial energy boost, mental clarity for some patients | Oura readiness, subjective energy |
| Weeks 2–4 | Sustained energy, enhanced cognition, improved mood, better sleep | HRV, sleep score, resting HR |
| Month 2 | Measurable HRV improvement, reduced inflammation | CRP, blood glucose, HbA1c |
| Month 3 | Significant cognitive enhancement, physical endurance improvement | VO2 max, full blood panel, DNA methylation |
Dripdok’s Proprietary Delivery Advantage #
We improved intracellular NAD+ uptake from the industry-standard 10–20% to 40–60% by modulating proprietary factors including AMPK pathway activation. This is why our results consistently outperform standard NAD+ IV protocols.
